Lorvotuzumab mertansine

DB12089InvestigationalProtein Based Therapies

Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.

Mechanism: Pharmacologically active on Neural cell adhesion molecule 1
Curator reviewed
Code names: BB-10901 · huN901-DM1 · IMGN-901

Resolves to

Compound

UNII0IVD6ASY0WCAS1008106-64-6

Targets

P13591NCAM1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

701Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lorvotuzumab mertansine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account